Analysts expect the company to post earnings of ($0.12) per share and revenue of $26.2120 million for the quarter. On average, analysts expect Vaxart to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year. Get Vaxart alerts:Vaxart Stock Up 1.7%OTCMKTS VXRT traded up $0.01 during trading hours on Tuesday, hitting $0.60. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 70,568 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Vaxart during the first quarter worth about $31,000.